Shigemasa Takamizawa, Tatsunori Shimoi, Masayuki Yoshida, Momoko Tokura, Shu Yazaki, Chiharu Mizoguchi, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, Yuki Kojima, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Emi Noguchi, Kazuki Sudo, Kan Yonemori
BACKGROUND: Routine measurement of tumor markers is not recommended in daily clinical practice for patients with cancer of unknown primary (CUP). We evaluated the diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with CUP. METHODS: We retrospectively reviewed the medical records of patients who were diagnosed with CUP between October 2010 and July 2015 at the National Cancer Center Hospital. The tumor markers of the patients were examined, including squamous cell carcinoma antigen, cytokeratin fraction, carcinoembryonic antigen, sialyl Lewis X, neuron-specific enolase, pro-gastrin-releasing peptide, α-fetoprotein, protein induced by vitamin K absence or antagonist II, prostate-specific antigen, soluble interleukin-2 receptor, carbohydrate antigen 19-9, cancer antigen 125, cancer antigen 15-3, NCC-ST-439 (ST439), elastase-1, human chorionic gonadotropin, and sialyl-Tn (STN)...
April 14, 2022: BMC Cancer